Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- 7 HLTH Announcements You Don’t Want to Miss (MedCity News)
- Practical Tips for Contracting, Part 2 (GI & Endoscopy News)
- GRAIL PATHFINDER 2 Results Show Galleri® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings (GRAIL)
- Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates (AJMC)
- St. Charles Health System Taps WovenX to Transform GI Access and Optimize Capacity (PR Newswire)
- United Digestive adds 5 gastroenterologists in 3 months (Becker’s GI & Endoscopy)
- Negotiated Prices for Large Insurers and Regional Differences in Employed Cardiology and GI Groups Revealed (Medscape)
- Health care in the USA: money has become the mission (The Lancet)
